Choledochoscope manometry about different drugs on the Sphincter of Oddi.
OBJECTIVE
To assess the effects of H(2)-receptor blocking pharmacon, protease inhibitor, and gastro kinetic agents on the human Sphincter of Oddi (SO) motility by choledochoscope manometry.


METHODS
One hundred and seventy-five patients with T tube installed after cholecystectomy and choledochotomy were assessed by choledochoscope manometry. They were randomly assigned into groups of H(2)-receptor blocking pharmacon, protease inhibitor, and gastro kinetic agents. The Sphincter of Oddi basal pressure (SOBP), amplitude (SOCA), frequency of contractions (SOF), duodenal pressure (DP), and common bile duct pressure (CBDP) were scored and analyzed.


RESULTS
SOBP and SOCA were significantly decreased after cimetidine administration, and no statistical difference was seen in the famotidine group. In the gabexate mesilate group, SOBP had decreased significantly. In the ulinastatin group, SOCA decreased when ulinastatin was given at the rate of 2500 U/min; when ulinastatin administration was raised to 5000 U/min, SOBP, SOF and SOCA all experienced a fall. SOBP and SOCA for domperidone and SOCA for mosapride groups all decreased distinctly after administration.


CONCLUSIONS
The regular dosage of cimetidine showed an inhibitory effect on the motility of SO, while famotidine had no obvious effects otherwise. Gabnexata mesilate, ulinastatin and gastro kinetic agents also showed inhibitory effects on the SO motility.
Kong
Jing
J
Department of General Surgery, Shengjing Hospital of China Medical University, Shenyang 110004, Liaoning Province, China.
Wu
Shuo-Dong
SD
Zhang
Xiao-Bo
XB
Li
Zhen-Sheng
ZS
Shi
Gang
G
Wang
Wei
W
Chen
Jun-Zhi
JZ
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D001549:Benzamides / Q000627:therapeutic use; D002763:Cholecystectomy; D002927:Cimetidine / Q000627:therapeutic use; D004294:Domperidone / Q000627:therapeutic use; D019723:Endoscopes; D015738:Famotidine / Q000627:therapeutic use; D005260:Female; D016670:Gabexate / Q000627:therapeutic use; D005765:Gastrointestinal Agents / Q000627:therapeutic use*; D006023:Glycoproteins / Q000627:therapeutic use; D006635:Histamine H2 Antagonists / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D008365:Manometry / Q000295:instrumentation*; D008875:Middle Aged; D009025:Morpholines / Q000627:therapeutic use; D009119:Muscle Contraction / Q000187:drug effects; D011312:Pressure; D015842:Serine Proteinase Inhibitors / Q000627:therapeutic use*; D009803:Sphincter of Oddi / Q000187:drug effects* / Q000503:physiopathology; D055815:Young Adult
D001549:Benzamides; D005765:Gastrointestinal Agents; D006023:Glycoproteins; D006635:Histamine H2 Antagonists; D009025:Morpholines; D015842:Serine Proteinase Inhibitors; D016670:Gabexate; D004294:Domperidone; D015738:Famotidine; D002927:Cimetidine; C062720:mosapride; C028665:urinastatin